

SNS Laboratories Limited

Regd. Off. : Office No. 322, 3rd Floor, S S Plaza, Commercial Complex, Mayfield Garden, Sector-47, Gurugram (Har.)-122001
E-mail : sns laboratories@gmail.com, Website : sns laboratories.in, CIN : L85110HR1985PLC022029

Date: 28.07.2022

To,
The Head-Listing & Compliances
Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No C 62, G - Block,
Opp. Trident Hotel, Bandra Kurla Complex, Bandra (E),
Mumbai - 400 098

Sub: Outcome of Board Meeting held on 28th July, 2022, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at its meeting held today i.e., on 28th July, 2022 at 12.30 p.m. and concluded at 1.30 pm has approved Unaudited Quarterly Financial Results for the quarter ended on 30th June, 2022 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The copy of Unaudited Quarterly Financial Results of the Company is enclosed herewith.

You are requested to take the above on your records and acknowledge the same.

Thanking You
Yours faithfully

For and on behalf of SNS Laboratories Limited


Dharmendra Gupta
(Director)
DIN: 07543296
Encl.: a/a



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2022 - IND-AS COMPLIANT

	Particulars	Three Months Ended for			Year Ended
		CURRENT QUARTER	PREVIOUS QUARTER	CORRESPONDING QUARTER	YEAR TO DATE FIGURES FOR PREVIOUS YEAR
		01.04.2022 to 30.06.2022 (₹)	01.01.2022 to 31.03.2022 (₹)	01.04.2021 to 30.06.2021 (₹)	01.04.2021 to 31.03.2022 (₹)
		Unaudited	Audited	Unaudited	Audited
I	Revenue From Operations:				
	Interest On Loan	-	-	-	-
	Sale of Diamond/Gold	-	-	-	-
	Sale of Shares	-	-	-	-
II	Other Income	-	-	-	-
III	Total Income (I+II)	-	-	-	-
IV	EXPENSES				
	Cost of Materials consumed	-	-	-	-
	Purchase of stock-in-trade :	-	-	-	-
	Purchase of Fabric	-	-	-	-
	Purchase of Diamond/Gold	-	-	-	-
	Purchase of Shares	-	-	-	-
	Changes in inventories of finished goods, WIP and stock-in-trade	-	-	-	-
	Employee benefits expenses	-	-	-	-
	Finance costs	-	-	-	-
	Depreciation and amortisation expenses	-	-	-	-
	Other expenses:	-	-	-	-
	Total expenses (IV)	-	-	-	-
V	Profit/(loss) before exceptional items and tax (I- IV)	-	-	-	-
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) before tax(V-VI)	-	-	-	-
VIII	Tax expense:				
	(1) Current tax	-	-	-	-
	(2) Deferred tax	-	-	-	-
	Total tax expenses	-	-	-	-
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	-	-	-	-
X	Profit/(loss) from discontinued operations	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	-	-	-	-
XIV	Other Comprehensive Income	-	-	-	-
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be re- classified to profit or loss	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-	-	-	-
XVI	Paid up equity share capital (Face value Rs. 10/- per share)	2,86,25,000	2,86,25,000	2,86,25,000	2,86,25,000
XVII	Earnings per equity share (for continuing operation):	-	-	-	-
	(1) Basic	-	-	-	-
	(2) Diluted	-	-	-	-
XVIII	Earnings per equity share (for discontinued operation):	-	-	-	-
	(1) Basic	-	-	-	-
	(2) Diluted	-	-	-	-
	See accompanying note to the financial results				



Notes :

- (1) The above unaudited financial results for the quarter ended 30th June, 2022 has been reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on 28th July, 2022.
- (2) The above results have been prepared in compliance with the recognition and measurement principles of the Companies (India Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards Amendment Rules, 2016) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable, beginning 1st April, 2017, the company has for the first time adopted Ind AS with a transition date of 1st April, 2016.
- (3) The format for above results as prescribed in SEBI's circular CIR/SFD/CMS/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's circular dated 5th July, 2016, Ind AS and Schedule III (Division-II) to the companies Act, 2013 applicable to companies that are required to comply with Ind AS.
- (4) Investor Compliants :
- Pending at the beginning of the quarter : 0
- Received during quarter : 0
- Disposed off during quarter : NA
- Unresolved at the end of the quarter : NA
- (5) Statement for reconciliation of net profit/ loss pursuant to SEBI Circular no. CIR/CFD/FAC/62/2016) dated July 05, 2016 as mentioned in the unaudited financial results for the quarter ended 30th June, 2022 compliant with Ind AS:

Nature of Adjustments	Quarter ended 30-6-2022	Year ended 31-3-2022
Net Profit/ Equity as per previous Indian GAAPs	-	-
Add/ (Less): Adjustments to Balance Sheet	-	-
Add/ (Less): Adjustments to Statement of Profit and Loss	-	-
Net Profit/ loss for the period as per Ind-AS	-	-
Other Comprehensive period (net of tax)	-	-
Total Comprehensive Income/ Equity as per Ind AS	-	-

- (7) Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.

For and on behalf of board of directors of

SNS LABORATORIES LIMITED


Dharmendra Gupta
Director
DIN: 07543296

Date: 28.07.2022
Place: New Delhi